How the Global Market for Reproductive Labor Is Shifting from Human Bodies Toward Engineered Biology

I. The Unbundling of Reproduction

An embryo can be created in one country, carried to term in another, and enter a third country’s legal system at birth.

The individuals involved may live under different legal systems and never interact directly outside the clinical and legal process. What connects them is an international network of fertility clinics, legal retainers, cryobanks, brokerage agencies, family courts, and consular authorities.

In 2008, the legal vulnerability of this network became visible in the case of Baby Manji Yamada. A Japanese married couple contracted a gestational carrier in Anand, India, using an anonymous Indian egg donor and the husband’s sperm. After the couple divorced prior to delivery, the intended mother no longer sought custody, while the genetic father faced obstacles in taking the child out of India. The case exposed a gap between the commercial surrogacy agreement, Indian administrative rules, and Japanese parentage and travel requirements. The Supreme Court of India disposed of the custody proceedings while permission for the child’s travel and passport remained under consideration (Supreme Court of India, Baby Manji Yamada v. Union of India, 2008). Manji ultimately left India for Japan in the care of her genetic father and grandmother after Indian authorities issued the necessary travel documentation and Japan granted a humanitarian visa (Oxford University Press, “Transnational Commercial Surrogacy: Contracts, Conflicts, and the Prospects of International Legal Regulation” in International Surrogacy and Child Welfare).

The case demonstrated an underlying shift: human reproduction, historically bound to a single female body, has become progressively unbundled into distinct commercial and biological services:

• Conception outside coitus: In vitro fertilization (IVF) relocated fertilization to an incubator.
• Genetics distinct from parenthood: Donor gametes separated biological lineage from social responsibility.
• Gestation separated from genetic lineage: Gestational surrogacy allowed a carrier with no genetic connection to gestate the embryo.
• Reproduction across international borders: Cross-border arrangements utilized differences in national regulations, medical costs, and legal regimes.
• Partial gestation outside the uterus: Partial ectogenesis is beginning to challenge one part of pregnancy’s biological role: sustaining extremely premature infants after delivery. Full replacement of human gestation remains speculative.

The critical structural question is what happens when this unbundling reaches its next phase. Surrogacy separated gestation from genetic parenthood. Emerging artificial womb research could eventually separate gestation from the human body itself.

This unbundling is sustained by two major sources of demand.

The first is medical necessity. The World Health Organization estimates that approximately one in six people of reproductive age experience infertility during their lifetime (WHO Infertility Fact Sheet, 2025). The WHO’s global guidance emphasizes that fertility care remains a major equity challenge, marked by high out-of-pocket costs and uneven geographical access. A global longitudinal study published in Human Reproduction, analyzing data across 204 countries and territories between 1990 and 2021, established that infertility prevalence has risen internationally and projected further increases through 2040 (Human Reproduction, Global Prevalence and Trends of Infertility, 2025). For people unable to safely carry a pregnancy, and for some single or male same-sex intended parents, gestational surrogacy can provide a route to having a genetically related child.

The second demand pool is elective. As documented by the Financial Times, recent reporting describes growing interest among wealthy Chinese clients in overseas surrogacy, including arrangements in the United States, Georgia, and Kyrgyzstan (Financial Times, “Chinese women turn to surrogates to avoid motherhood penalty”, 2026). In high-pressure professional environments, some clients explore surrogacy not solely because of clinical infertility, but because pregnancy imposes substantial career penalties, physical risks, and prolonged professional leave.

When reproduction is disaggregated into separate commercial stages, gestation ceases to be an immutable biological condition. It becomes an operational choice that can be negotiated, contracted, and relocated.

II. The Price of a Pregnancy: Institutional Arbitrage

Pregnancy spans roughly 40 weeks from the conventional starting point used in obstetric dating, regardless of where it takes place. In the global marketplace, however, the financial compensation and service fees assigned to that pregnancy diverge substantially based on national jurisdiction.

Because commercial surrogacy is decentralized, comprehensive official global statistics do not exist. Published prices across jurisdictions also reflect fundamentally different service packages, legal safeguards, and medical contingencies rather than standardized commodities. Nonetheless, specialist industry surveys and legal monitoring provide documented examples of the scale of this variation:

• In the United States, full surrogacy journeys commonly cost well into six figures, with complex arrangements reported up to $300,000 (Financial Times, 2026).
• In the Republic of Georgia, published agency packages can run into the tens of thousands of dollars, substantially below the cost of many U.S. arrangements (Financial Times, 2026; The Surrogacy Insider, 2026).

The resulting price difference can be substantial, even though the underlying biological process is broadly similar.

This pricing divergence is not driven by the core biology. The underlying procedures are technically similar across many established IVF systems, although laboratory standards, protocols, and clinical outcomes vary substantially by clinic and jurisdiction. A substantial part of the price difference reflects differences in legal protection, insurance, medical infrastructure, agency costs, and jurisdictional risk.

When commissioning parents choose high-cost American jurisdictions, part of the premium reflects legal enforceability and statutory protection. Under California Family Code § 7962, California law permits intended parents to seek a parentage judgment before or after birth (California Legislative Information, Cal. Fam. Code § 7962). When statutory requirements are satisfied, the judgment establishes the intended parents as the legal parents and provides that the surrogate and her spouse or partner are not parents of the child (California Courts Self-Help Center).

For arrangements conducted in the United States, citizenship and parentage are governed by US law, while the legal position of the intended parents depends on the applicable state rules. Birth in the United States can provide a major citizenship advantage under the Fourteenth Amendment (U.S. Supreme Court, Trump v. Barbara, 2026; Legal Information Institute, U.S. Constitution, Fourteenth Amendment), but cross-border cases still involve documentation and parentage requirements (U.S. Department of State, ART and Surrogacy Guidance).

In some lower-cost destinations, intended parents may trade greater institutional uncertainty for financial savings. They take on the operational risks of ambiguous parentage statutes, uncodified court procedures, sudden regulatory interventions, and contested consular reviews. The cross-border market functions through institutional arbitrage: balancing legal stability, judicial enforceability, and sovereign risk against capital expenditure.

III. The Global Reproductive Service Network

Describing commercial surrogacy as a private contract between a commissioning couple and a carrier overlooks the complex network that coordinates international reproduction.

Different stages can be distributed across jurisdictions, allowing intended parents and intermediaries to navigate differences in cost, medical capacity, and legal rules:

• Intended Parents: Providing capital, commissioning agreements, and legal instructions.
• Brokers and Agencies: Coordinating surrogate matching, trust fund escrows, clinic schedules, and cross-border logistics.
• Gamete Providers and Cryobanks: Exporting cryopreserved oocytes or sperm internationally.
• Clinical and Embryological Teams: Performing IVF cycles, embryo culture, and pre-implantation screening, followed by prenatal monitoring, labor delivery, and neonatal care.
• Legal and Judicial Authorities: Drafting contracts, litigating parentage, and securing judicial parentage decrees where required.
• Consular and Immigration Authorities: Reviewing citizenship and parentage evidence, conducting DNA testing where required, and issuing travel documents.

Consider a hypothetical arrangement: an intended couple residing in Germany, where domestic law places significant restrictions on surrogacy and egg donation, sources donor oocytes from a certified clinic in Spain, ships cryopreserved sperm to a medical center in the Czech Republic for fertilization, transfers the blastocyst into a gestational carrier residing in Georgia, and retains specialized immigration solicitors to process travel visas for repatriation.

When biological, gestational, and social parentage are intentionally separated across borders, some domestic legal systems can struggle to accommodate the resulting relationships.

IV. The Paper Border: Parentage, Citizenship, and the Limits of International Law

The central vulnerability of the cross-border reproductive trade is that medical capability has expanded far faster than international legal coordination. There is no binding global convention establishing universal recognition of parentage across borders.

For over a decade, the Hague Conference on Private International Law (HCCH) examined the feasibility of an international instrument to recognize foreign judicial decisions concerning legal parentage. However, in March 2026, the Council on General Affairs and Policy of the HCCH decided not to convene a Special Commission on the Parentage/Surrogacy Project at this stage (HCCH Council Conclusions, March 2026). Instead, the Council instructed the Permanent Bureau to continue monitoring developments and report back ahead of its 2028 meeting.

With no new international convention moving forward at this stage, cross-border parentage remains largely dependent on domestic law, private international law, and judicial mechanisms that differ between jurisdictions.

Three problems recur:

1. Conflicting Maternal Baselines: In the United Kingdom, Section 33 of the Human Fertilisation and Embryology Act 2008 provides that the woman who carries a child is the legal mother, regardless of genetic relation or foreign legal documents (UK Legislation, HFEA 2008). Commercial surrogacy agreements are unenforceable under UK law. Intended parents must undergo a formal court proceeding after birth to obtain a Parental Order transferring legal parenthood (GOV.UK, Surrogacy Legal Rights Guidance). This can leave intended parents without the final UK legal status they seek until the parental-order process is completed.
2. Citizenship and Repatriation Delays: The U.S. Department of State explicitly warns that children born through international ART and surrogacy can encounter severe citizenship hurdles (U.S. Department of State, ART Guidance). Under the U.S. Immigration and Nationality Act, a child born abroad does not automatically acquire citizenship unless statutory transmission requirements—including a verified biological connection to a U.S. citizen parent—are legally satisfied. In some cross-border arrangements, failures to satisfy citizenship or parentage requirements can delay documentation and the child’s departure from the country of birth.
3. The Human Rights Equilibrium: The European Court of Human Rights addressed this tension in its landmark judgments in Mennesson v. France and Labassee v. France (ECHR HUDOC, Mennesson v. France and Labassee v. France, 2014). French authorities had refused to transcribe California birth certificates for children born through gestational surrogacy, arguing that recognizing the contracts would violate domestic public policy. The Court held that France’s refusal to recognize the children’s relationship with their biological father violated the children’s right to respect for private life under Article 8, while leaving states considerable discretion over whether to permit surrogacy domestically. The Court therefore distinguished between a state’s freedom to prohibit surrogacy domestically and its obligation to protect the child’s private-life interests once a parent-child relationship has been established abroad.

V. The Balloon Effect: How Bans Displace the Market

Because global demand for reproductive labor remains persistent, prohibition in one country has not always extinguished the trade. In several documented cases, commercial activity reappeared in jurisdictions where arrangements remained available or weakly regulated.

This displacement pattern is visible across several documented transitions over the past two decades:

• The Closure of Asian Hubs: During the 2000s, clinics in Gujarat helped establish India as a major hub for affordable commercial surrogacy. Concerns over exploitation, lack of post-birth care, and legal disputes over foreign infants led to a phased shutdown. A 2015 Ministry of Home Affairs notification had already barred foreign nationals and Overseas Citizen of India (OCI) cardholders from commissioning surrogacy in India (Press Information Bureau, Ministry of Home Affairs, 2015). The subsequent statutory framework, brought into force in January 2022 under the Surrogacy (Regulation) Act, 2021, and its 2022 Rules, codified this restriction and limited eligibility to specified Indian intending couples meeting statutory medical criteria and an Indian widow or divorcee aged 35 to 45, while prohibiting commercial surrogacy entirely (India Code, Surrogacy (Regulation) Act, 2021).
• The Southeast Asian Transit: Following restrictions in India and Thailand in 2015, commercial agencies rapidly relocated operations into Cambodia. Soon afterward, Cambodian authorities intervened, arrested facilitators, and prohibited commercial surrogacy (Reuters, “Cambodia bans commercial surrogacy”, 2016; The Guardian, “Cambodia bans commercial surrogacy”, 2016).
• The Shift to Eastern Europe: After restrictions in India and Southeast Asia, Ukraine and Georgia became important destinations in the international surrogacy market, although the geography has continued to change (PubMed Central / Reproductive Biomedicine Online). The Russian invasion of Ukraine in 2022 introduced acute operational disruptions for clinic operations and infant evacuations.
• The Caucasus and New Corridors: In 2023, a draft law sought to restrict commercial surrogacy for foreign nationals, but the proposal stalled in parliament and was not enacted (Radio Free Europe / Radio Liberty, 2023; Parliament of Georgia). Georgia continues to have a statutory framework recognizing qualifying surrogacy arrangements (Legislative Herald of Georgia, Law on Health Care), although eligibility for foreign intended parents and any proposed restrictions remain jurisdiction-specific and time-sensitive. Concurrently, reporting by the Financial Times documents growing interest from international clients looking to destinations such as Georgia and Kyrgyzstan (Financial Times, 2026).

These episodes are consistent with a displacement pattern: when commercial surrogacy becomes unavailable in one jurisdiction, some demand and intermediary activity can move to jurisdictions where arrangements remain available.

VI. The Asymmetry of Risk: The Hidden Health Economics

Commercial surrogacy is structured through legal and financial contracts—”gestational service agreements,” “living stipends,” and “escrow releases.” This transactional framing can obscure an underlying reality: gestation remains a form of bodily labor that involves non-transferable physical risks.

In a commercial arrangement, the intended parents assume financial and emotional risk. The surrogate assumes the physical risk of pregnancy and delivery.

Professional standards emphasize that gestational carriers must retain full decision-making authority over medical treatments and should receive independent legal counsel and informed consent (ASRM Practice Committee Guidance). Yet the biological realities of pregnancy cannot be contracted away:

• Carrier-Specific and ART Outcomes: A comprehensive 2024 systematic review and meta-analysis published in the medical literature found that gestational-carrier pregnancies were associated with higher odds of hypertensive disorders of pregnancy compared to spontaneously conceived pregnancies (PubMed Meta-Analysis on Gestational Carriers, 2024). The same meta-analysis found lower odds of cesarean delivery when gestational carriers were compared with non-carrier ART patients. The authors note that gestational carriers are typically highly screened and selected, but the comparison does not establish that screening itself caused the difference.
• Risks of Multiple Gestation: Historically, clinics attempted to maximize pregnancy rates per cycle by transferring multiple embryos. Multiple-embryo transfer can increase the risk of multiple gestation, which is why the American Society for Reproductive Medicine strongly recommends single-embryo transfer in gestational-carrier cycles to reduce the risks of preterm labor, preeclampsia, and neonatal morbidity (ASRM Practice Committee Guidance).
• Postpartum Realities: Postpartum recovery continues after delivery, while the legal and emotional consequences of relinquishing the child vary among carriers.

This division of labor underpins the ethical debate surrounding cross-border surrogacy: can financial compensation make the assumption of biological medical risks economically equitable? When marked income disparities exist between clients and carriers, the boundary between voluntary employment and economic necessity remains controversial.

VII. The Mechanized Placenta: Preclinical Science vs. Speculative Ectogenesis

The legal disputes, geopolitical disruptions, and ethical debates surrounding human surrogacy explain why biomedical engineering is investigating an alternative: ectogenesis, the gestation of life outside the human body.

Public discussions often conflate artificial wombs into a single futuristic concept. In laboratory research, however, researchers generally distinguish between two very different technological goals: partial ectogestation for extremely premature infants and complete ectogenesis from early development onward.

1. Complete Ectogenesis: Culturing an embryo from in vitro fertilization through gastrulation, organogenesis, and the full nine months of fetal development entirely within a machine. As of October 2026, complete ectogenesis has not been demonstrated and remains far beyond the current clinical state of the technology.
2. Partial Ectogenesis (Extra-Uterine Life Support): Sustaining an extremely premature infant (born near the threshold of viability, roughly 22 to 25 weeks of gestation) in an artificial amniotic environment equipped with an extracorporeal oxygenation circuit. This technology does not aim to replace pregnancy; it aims to replace mechanical ventilators in the neonatal intensive care unit (NICU).

What Exists Now

A prominent scientific program in partial ectogenesis is the EXTEND (Extra-uterine Environment for Newborn Development) platform, developed by Dr. Alan Flake and his team at the Children’s Hospital of Philadelphia (CHOP), in partnership with Vitara Biomedical.

The EXTEND system addresses the fundamental limitation of traditional neonatal care: extremely premature lungs are highly vulnerable to injury from ventilation and oxygen exposure, while prematurity itself carries risks including bronchopulmonary dysplasia, intraventricular hemorrhage, and neurodevelopmental impairment.

EXTEND bypasses the lungs entirely:

• The premature subject is submerged in a sterile, fluid-filled chamber (“biobag”) filled with synthetic amniotic fluid, which the fetus breathes and swallows naturally.
• Circulation is maintained through an artificial placenta: the fetus’s umbilical vessels are cannulated and connected to an external, low-resistance gas-exchange oxygenator.
• Crucially, the system is pumpless, allowing blood circulation to be driven by the fetal heart without an external blood pump.

What the Preclinical Evidence Shows

Preclinical data from the CHOP team has demonstrated the physiological potential of the system. In a landmark 2024 animal study published in Pediatric Research, researchers maintained 10 extremely premature fetal lambs (mean gestational age of 91.6 days, representing an extremely premature developmental stage with closer neurodevelopmental equivalence to approximately 24–28 weeks of human gestation) for an average of 13.5 days, with one animal maintained continuously for 21 days (Pediatric Research, EXTEND Study, 2024). The study reported stable hemodynamics, organ growth and physiologic cardiac function. Histologic brain analysis showed no difference from controls, and the treatment was not associated with intraventricular hemorrhage or white-matter injury in the study animals.

However, moving from successful animal experiments to human trials involves significant technical hurdles. A comprehensive 2026 systematic review evaluating 22 animal studies on artificial womb technology found that while the four-week maintenance demonstrated in early landmark biobag experiments proved the concept, it is not yet a consistently reproducible clinical standard across wider trials (PubMed Systematic Review on Artificial Wombs, 2026).

Preclinical research continues to grapple with engineering vulnerabilities:

• Circuit Thrombosis: Circuit thrombosis can require anticoagulation, creating a difficult trade-off between clot prevention and bleeding risk (PubMed Systematic Review on Artificial Wombs, 2026).
• Cannulation Failure: Maintaining stable, non-occlusive connections to delicate umbilical vessels over weeks of fetal growth and spontaneous movement remains mechanically challenging.
• Hemodynamic and Metabolic Drift: Animal models frequently exhibit progressive metabolic acidosis, fluctuating systemic vascular resistance, and fluid retention over extended runs.
• Absence of Human Trials: As of October 2026, no human clinical trial of an artificial womb system has been conducted (PubMed Systematic Review on Artificial Wombs, 2026).

The preclinical evidence supports a measured conclusion: artificial womb technology represents a potential biomedical intervention for extreme prematurity, but it has not yet established verified safety or clinical efficacy in human patients.

VIII. The Device Pathway: Regulating the Neonatal Bridge

How will artificial gestation enter clinical medicine? The first clinical pathway is likely to be through neonatal medicine and medical-device regulation rather than elective reproductive care.

The regulatory framework for considering such technology is beginning to take shape. The FDA’s 2023 discussion was focused on extremely premature infants rather than elective replacement of pregnancy (U.S. FDA Pediatric Advisory Committee Meeting, 2023). Materials considered by the committee contemplated first-in-human studies involving infants around 22 to 24 weeks of gestation, with longer-term developmental outcomes among the issues requiring consideration.

The discussions outlined key areas of focus:

• Scope of Application: Explicitly focused on critically ill premature neonates rather than elective gestational substitution.
• The Placental Challenge: The committee highlighted that current commercial gas-exchange devices cannot fully replicate natural placental biology. The biological placenta is not merely an oxygenator; it is an active metabolic organ that clears fetal waste, synthesizes hormones, modulates immune tolerance, and regulates developmental signaling.

Vitara Biomedical, the spin-out commercializing the CHOP technology, operates strictly within this medical device framework (Vitara Biomedical). Vitara’s official disclosures explicitly state that its investigational EXTEND device is limited by federal law to investigational use, has not received marketing clearance or approval from the FDA or any foreign regulatory authority, and is not commercially available.

This regulatory framing is critical. If artificial gestation enters clinical medicine, it will do so under the umbrella of neonatal emergency medicine. If the technology eventually proves safe and effective, it could shift clinical definitions and expectations around the limits of viability.

IX. The Demographic Engine: Where the Womb Goes Next

While artificial-womb technology is developing as a clinical bridge for neonatologists, its longer-term possibilities intersect with a world of persistently low fertility and rapid population aging.

Several advanced economies, particularly in East Asia, now have fertility rates far below replacement level (2.1 births per woman). According to comparative demographic datasets published by the OECD in 2025, fertility across much of the region is at very low levels (OECD Fertility Rates Data, 2025):

• Japan: 1.40
• China: 1.24
• South Korea: 1.13

In China, official data published by the National Bureau of Statistics showed 7.92 million births against 11.31 million deaths in 2025, yielding a negative natural population growth rate of −2.41 per thousand, with citizens aged 60 and older comprising 23.0 percent of the total population (National Bureau of Statistics of China, 2025).

This demographic reality raises an inevitable question: if aging nation-states require more children to sustain pension systems, labor markets, and economic productivity, could governments eventually look to artificial gestation as strategic demographic infrastructure?

Here, structural analysis requires caution. A technology-centric narrative suggests that reducing the physical burden of pregnancy will automatically restore birth rates. However, demographic research shows that the primary obstacle to childbearing is not biological gestation itself.

The United Nations Population Fund (UNFPA), in its 2025 State of World Population report, documented that one in five adults globally expects to have fewer children than they desire (UNFPA State of World Population Report, 2025). The survey identified the structural drivers of this gap:

1. High costs of housing, education, and parenthood.
2. Widespread employment precarity and demanding workplace cultures.
3. Inadequate, expensive childcare infrastructure.
4. Unequal distributions of domestic and emotional labor.
5. Economic anxiety over long-term stability and climate risk.

Research on East Asian pronatalist policy published in Asian Population Studies / Taylor & Francis in 2025 demonstrates that financial incentives and childcare measures have not, on their own, overcome the broader structural barriers shaping fertility decisions (Taylor & Francis Online, Comparative East Asian Pronatalist Policy Study, 2025).

Artificial gestation could remove some of the physical and career burdens associated with pregnancy, while introducing its own medical and logistical risks. It cannot solve the price of housing, stabilize labor contracts, or provide affordable twenty-year childcare. Viewing ectogenesis as a silver bullet for demographic decline mistakes a biological component of reproduction for its socioeconomic whole.

X. Three Competing Futures

The convergence of global surrogacy markets, reproductive biotechnology, and demographic pressure points toward three divergent structural scenarios:

Scenario A: The Medical Womb (The NICU Bridge)

• Mechanics: The technology remains confined to neonatal intensive care. Clinical trials establish safety benchmarks for infants born around the limits of viability, with the technology potentially reducing complications associated with conventional ventilation. Engineering complexities and bioethical regulations keep the system confined to neonatal care rather than allowing expansion backward toward early gestation.
• Impact on Surrogacy: Negligible. Human gestational surrogacy continues to operate as the primary method for outsourcing pregnancy, characterized by cyclical regulatory bans, geographical migration, and legal vulnerability.

Scenario B: The Commercial Womb (Market Commodification)

• Mechanics: Over decades, private capital and assisted reproductive technology networks advance partial ectogenesis earlier into gestation, successfully bridging with late-stage in vitro embryo culture. The technology enters deregulated private markets as an expensive, elective reproductive service.
• Impact on Surrogacy: A successful mechanical gestation system could reduce some of the legal and bodily disputes associated with human surrogacy, while creating an entirely new set of questions around embryo ownership, fetal status, parentage, and regulation. Commercial intended parents could transition toward mechanical systems, potentially reducing demand for some international surrogacy arrangements.

Scenario C: The Strategic Womb (State Infrastructure)

• Mechanics: In a more speculative scenario, a state facing severe demographic contraction could treat reproductive technology as strategic infrastructure and subsidize large-scale artificial gestation, coupling the technology with state-funded infant care and educational programs.
• Impact on Surrogacy: Reproduction is institutionalized and brought onshore. The process moves from an outsourced international market to a state-controlled domestic utility.

Conclusion: The Architecture of Generation

The trajectory of human reproduction over the past half-century has followed a consistent pattern: reproductive functions have become progressively separated from the biological body.

In vitro fertilization demonstrated that conception could occur without intercourse. Gestational surrogacy proved that pregnancy could function as a contracted commercial service across international borders.

Artificial-womb technology could become the next major step in this trajectory. While near-term clinical reality remains focused on keeping fragile premature infants alive in hospital incubators, the research infrastructure for a possible future extension is already being developed.

Global reproductive markets made gestation transferable across households and, increasingly, across borders. In the decades ahead, biotechnology may transform it into an engineered piece of clinical hardware.

If that transition occurs, the fundamental question will no longer be only who can become pregnant, but who owns, finances, and regulates the technology of human generation.